Vaxcyte COO sells 2,250 shares under 10b5-1 plan

Vaxcyte, Inc. chief operating officer Jim Wassil reported open-market sales of 2,250 shares of common stock.

Rhea-AI Filing Summary

Vaxcyte, Inc. chief operating officer Jim Wassil reported open-market sales of 2,250 shares of common stock. On April 1, 2026, he sold 1,412 shares at a weighted-average price of $58.138 and 838 shares at a weighted-average price of $58.932.

After these sales, he directly owned 162,994 shares of Vaxcyte common stock. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. A footnote also describes prior share transfers to his ex-spouse pursuant to a divorce settlement domestic relations order.

Insider Trade Summary 10b5-1

Net Seller: 2,250 shares

Net Sell 2 txns

Insider Wassil Jim

Role CHIEF OPERATING OFFICER

Sold 2,250 shs ($131K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,412	$58.138	$82K
Sale	Common Stock	838	$58.932	$49K

Holdings After Transaction: Common Stock — 162,994 shares (Direct)

Footnotes (4)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
2. F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.695 to $58.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. F4. The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On March 25 and 26, 2026, the Reporting Person transferred 962 and 612 shares, respectively, of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.

Key Figures

Total shares sold: 2,250 shares First sale size: 1,412 shares First sale price: $58.138 per share +5 more

8 metrics

Total shares sold 2,250 shares Open-market sales on April 1, 2026

First sale size 1,412 shares Common stock sold at weighted-average $58.138

First sale price $58.138 per share Weighted-average price for 1,412-share sale

Second sale size 838 shares Common stock sold at weighted-average $58.932

Second sale price $58.932 per share Weighted-average price for 838-share sale

Shares held after trades 162,994 shares Direct ownership after April 1, 2026 sales

Divorce transfer March 25 962 shares Transferred to ex-spouse under domestic relations order

Divorce transfer March 26 612 shares Transferred to ex-spouse under domestic relations order

Key Terms

Rule 10b5-1 trading plan, weighted-average price, domestic relations order, Section 16(a), +1 more

5 terms

Rule 10b5-1 trading plan financial

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported is a weighted-average price. The shares were sold at prices ranging from $57.695 to $58.69."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

domestic relations order regulatory

"pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended."

Section 16(a) regulatory

"Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings."

beneficial ownership financial

"Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaxcyte (PCVX) COO Jim Wassil report in this Form 4?

COO Jim Wassil reported selling 2,250 Vaxcyte common shares in open-market trades. The sales occurred on April 1, 2026 under a pre-arranged Rule 10b5-1 trading plan and left him holding 162,994 shares directly.

How many Vaxcyte (PCVX) shares did the COO sell and at what prices?

He sold 1,412 shares at a weighted-average price of $58.138 and 838 shares at a weighted-average price of $58.932. These open-market sales totaled 2,250 shares of Vaxcyte common stock on April 1, 2026.

How many Vaxcyte (PCVX) shares does the COO hold after these transactions?

After the reported sales, COO Jim Wassil directly owns 162,994 shares of Vaxcyte common stock. This post-transaction holding figure comes from the Form 4 and reflects his remaining direct ownership position following the April 1, 2026 trades.

Were the Vaxcyte (PCVX) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted on December 9, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio management from discretionary market-timed transactions.

Does the Vaxcyte (PCVX) Form 4 mention any share transfers related to a divorce settlement?

Yes. A footnote explains that on March 25 and 26, 2026, the reporting person transferred 962 and 612 shares, respectively, to his ex-spouse under a divorce settlement domestic relations order, and he will no longer report beneficial ownership of those shares.

What does weighted-average price mean in this Vaxcyte (PCVX) insider sale filing?

Weighted-average price means multiple trades occurred within a price range and are reported as a single average price. The filing notes ranges of $57.695–$58.69 and $58.74–$59.215 and offers full trade-by-trade details to regulators or shareholders upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		1,412	D	$58.138(2)	165,406	D
Common Stock	04/01/2026		S(1)		838	D	$58.932(3)	162,994(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

2. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.695 to $58.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On March 25 and 26, 2026, the Reporting Person transferred 962 and 612 shares, respectively, of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)